I recently came across some exciting news about a new treatment for patients with PIK3CA-mutated breast cancer. Alpelisib, a targeted therapy drug, has shown promise in improving the outcomes for these patients. This breakthrough could potentially benefit around 40% of people with hormone receptor-positive, HER2-negative advanced breast cancer. The best part is that Alpelisib works alongside hormone therapy, increasing its effectiveness and providing new hope for those affected. I can't wait to see how this development progresses and improves the lives of breast cancer patients in the future.
